What's in M.D. Anderson Cancer Center's pipeline?

M.D. Anderson Cancer Center has 71 drugs in our index: 29 marketed, 0 filed, 19 in Phase 3, 5 in Phase 2, 10 in Phase 1.

Which companies overlap with M.D. Anderson Cancer Center's portfolio?

Top competitors by shared drug class: Sanofi, GlaxoSmithKline, Nanfang Hospital, Southern Medical University, Ain Shams University, Genzyme, a Sanofi Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/m-d-anderson-cancer-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

M.D. Anderson Cancer Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

M.D. Anderson Cancer Center pipeline: 29 marketed, 0 filed, 19 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

29 marketed 0 filed 19 Phase 3 5 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fentanyl Nasal Spray	Fentanyl Nasal Spray	marketed
Methoxsalen+ECP	Methoxsalen+ECP	marketed	Photochemotherapy agent		Oncology
6-Thioguanine	6-Thioguanine	marketed
Erwinase	Erwinase	marketed			Oncology
Ibritumomab Tiuxetan (Zevalin)	Ibritumomab Tiuxetan (Zevalin)	marketed	Radioimmunotherapy agent; anti-CD20 monoclonal antibody	CD20	Oncology
Pegylated liposomal doxorubicin hydrochloride	Pegylated liposomal doxorubicin hydrochloride	marketed	Anthracycline chemotherapy (liposomal formulation)	Topoisomerase II, DNA	Oncology
Gleevec	Gleevec	marketed		Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X	Oncology
Hydromorphone PCA	Hydromorphone PCA	marketed
ABLC	ABLC	marketed			Oncology
PCV20	PCV20	marketed			Other
VUEWAY	VUEWAY	marketed			Other
Vitamin C (Ascorbic Acid)	Vitamin C (Ascorbic Acid)	marketed	Antioxidant / Micronutrient		Oncology

Therapeutic area mix

Oncology · 31
Other · 18
Cardiovascular · 4
Immunology · 1
Immunology / Hematology-Oncology · 1
Immunology, Hematology, Transplantation · 1
Nutrition · 1
Pain Management / Neurology · 1
Bone metabolism / Rheumatology · 1
Toxicology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi · 4 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Nanfang Hospital, Southern Medical University · 3 shared drug classes
Ain Shams University · 3 shared drug classes
Genzyme, a Sanofi Company · 2 shared drug classes
Gustave Roussy, Cancer Campus, Grand Paris · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Amgen · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for M.D. Anderson Cancer Center:

Cite this brief

Drug Landscape (2026). M.D. Anderson Cancer Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/m-d-anderson-cancer-center. Accessed 2026-05-17.